Updated Mar 21, 2026 by GSK
GSK reported total Q1 2025 sales of £7.5 billion, representing a 2% increase at actual exchange rates (AER) and 4% at constant exchange rates (CER).
Specialty Medicines served as the primary growth driver, with sales rising 17% to £2.9 billion.
Oncology and Respiratory, Immunology, and Inflammation segments saw significant growth, with sales increasing by 53% to £0.4 billion and 28% to £0.8 billion, respectively.
HIV sales reached £1.7 billion in Q1 2025, marking a 7% increase compared to the previous period.
Vaccines sales declined by 6% to £2.1 billion, largely impacted by a 7% decrease in Shingrix sales to £0.9 billion.
Meningitis vaccine sales for the first quarter of 2025 totaled £0.4 billion.
GSK reported total Q1 2025 sales of £7.5 billion, representing a 2% increase at actual exchange rates (AER) and 4% at constant exchange rates (CER).
Specialty Medicines served as the primary growth driver, with sales rising 17% to £2.9 billion.
Oncology and Respiratory, Immunology, and Inflammation segments saw significant growth, with sales increasing by 53% to £0.4 billion and 28% to £0.8 billion, respectively.
HIV sales reached £1.7 billion in Q1 2025, marking a 7% increase compared to the previous period.
Vaccines sales declined by 6% to £2.1 billion, largely impacted by a 7% decrease in Shingrix sales to £0.9 billion.
Meningitis vaccine sales for the first quarter of 2025 totaled £0.4 billion.